Shanghai Pharma Eyes Acquisitions In The U.S., Europe
This article was originally published in PharmAsia News
Shanghai Pharmaceutical Holdings Co. Ltd. plans to establish a base overseas through acquisitions targeting midsize drug makers in Europe and the U.S. within the next six to12 months, said Ge Jianqiu, the distributor's vice president, at a performance announcement conference
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.